Metagenomi is a Biotech company. It has raised $300M in total funding. Latest round: Series B.
Metagenomi funding overview
Metagenomi is a Biotech company. Metagenomi has raised $300M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series B announced in January 2022. The round record for Metagenomi runs through 2022; nothing later has been disclosed. Investors on record include PFM Health Sciences, Farallon Capital Management, Moderna, Leaps by Bayer, Bristol Myers Squibb, Novo Holdings A/S and 10 others. 16 distinct backers are named across the disclosed rounds.
Metagenomi at a glance
Total raised
$300M
Latest round
Series B
Latest round date
January 2022
Industry
Biotech
Notable investors
PFM Health Sciences, Farallon Capital Management, Moderna, Leaps by Bayer, Bristol Myers Squibb, Novo Holdings A/S, Eventide Asset Management, Deep Track Capital
Frequently asked about Metagenomi funding
How much has Metagenomi raised?
Metagenomi has raised $300M in total disclosed funding across the rounds on record.
Who has invested in Metagenomi?
PFM Health Sciences, Farallon Capital Management, Moderna, Leaps by Bayer, Bristol Myers Squibb, Novo Holdings A/S are named among the investors backing Metagenomi.
What was the latest Metagenomi funding round?
The most recent disclosed round is a Series B, announced in January 2022.
Where is Metagenomi based?
No headquarters location is disclosed for Metagenomi.
What sector does Metagenomi operate in?
Metagenomi is tracked under Biotech, with $300M in disclosed funding.
When did Metagenomi last raise?
The last disclosed Metagenomi round closed in January 2022 at Series B.
We update the Metagenomi record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies and their backers are listed below.
